• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·1760.TW
Share

Panion & Bf Biotech Inc. Stocks

NT$ 58.5Last Updated 14.08.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 157.18M

NT$ 58.5
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical aesthetics, renal care, respiratory health, and gastrointestinal support. Beyond these, the company also provides oral medications, topical treatments, and an array of hygiene products like hand, mechanical, and skin disinfectants, alongside body lotions. Additionally, Panion & Bf Biotech supplies veterinary health solutions, notably surgical and dermatological prescriptions for animals. Established in 1976, the company maintains its corporate headquarters in Taipei, Taiwan.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.08.2026 16:01

Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt

15.08.2026 13:01

A New Leader from China, Billionaires in Soccer, and Ray Dalio's Party

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

15.08.2026 02:58

Shares of U.S. drone manufacturers surged following Trump's new tariffs

15.08.2026 02:44

The market is unfazed by the stock decline: Wall Street's fear index is at its lowest level since December

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026